152 related articles for article (PubMed ID: 21297272)
1. Time course of glucose metabolism in relation to cognitive performance and postmortem neuropathology in Met146Val PSEN1 mutation carriers.
Schöll M; Almkvist O; Bogdanovic N; Wall A; Långström B; Viitanen M; Nordberg A
J Alzheimers Dis; 2011; 24(3):495-506. PubMed ID: 21297272
[TBL] [Abstract][Full Text] [Related]
2. Clinical characterization of a presenilin 1 mutation (F177S) in a family with very early-onset Alzheimer's disease in the third decade of life.
Hausner L; Tschäpe JA; Schmitt HP; Hentschel F; Hartmann T; Frölich L
Alzheimers Dement; 2014 Mar; 10(2):e27-39. PubMed ID: 23850332
[TBL] [Abstract][Full Text] [Related]
3. Diverging longitudinal changes in astrocytosis and amyloid PET in autosomal dominant Alzheimer's disease.
Rodriguez-Vieitez E; Saint-Aubert L; Carter SF; Almkvist O; Farid K; Schöll M; Chiotis K; Thordardottir S; Graff C; Wall A; Långström B; Nordberg A
Brain; 2016 Mar; 139(Pt 3):922-36. PubMed ID: 26813969
[TBL] [Abstract][Full Text] [Related]
4. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.
Schöll M; Wall A; Thordardottir S; Ferreira D; Bogdanovic N; Långström B; Almkvist O; Graff C; Nordberg A
Neurology; 2012 Jul; 79(3):229-36. PubMed ID: 22700814
[TBL] [Abstract][Full Text] [Related]
5. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
6. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study.
Gordon BA; Blazey TM; Su Y; Hari-Raj A; Dincer A; Flores S; Christensen J; McDade E; Wang G; Xiong C; Cairns NJ; Hassenstab J; Marcus DS; Fagan AM; Jack CR; Hornbeck RC; Paumier KL; Ances BM; Berman SB; Brickman AM; Cash DM; Chhatwal JP; Correia S; Förster S; Fox NC; Graff-Radford NR; la Fougère C; Levin J; Masters CL; Rossor MN; Salloway S; Saykin AJ; Schofield PR; Thompson PM; Weiner MM; Holtzman DM; Raichle ME; Morris JC; Bateman RJ; Benzinger TLS
Lancet Neurol; 2018 Mar; 17(3):241-250. PubMed ID: 29397305
[TBL] [Abstract][Full Text] [Related]
7. PET of brain amyloid and tau in mild cognitive impairment.
Small GW; Kepe V; Ercoli LM; Siddarth P; Bookheimer SY; Miller KJ; Lavretsky H; Burggren AC; Cole GM; Vinters HV; Thompson PM; Huang SC; Satyamurthy N; Phelps ME; Barrio JR
N Engl J Med; 2006 Dec; 355(25):2652-63. PubMed ID: 17182990
[TBL] [Abstract][Full Text] [Related]
8. Worldwide distribution of PSEN1 Met146Leu mutation: a large variability for a founder mutation.
Bruni AC; Bernardi L; Colao R; Rubino E; Smirne N; Frangipane F; Terni B; Curcio SA; Mirabelli M; Clodomiro A; Di Lorenzo R; Maletta R; Anfossi M; Gallo M; Geracitano S; Tomaino C; Muraca MG; Leotta A; Lio SG; Pinessi L; Rainero I; Sorbi S; Nee L; Milan G; Pappatà S; Postiglione A; Abbamondi N; Forloni G; St George Hyslop P; Rogaeva E; Bugiani O; Giaccone G; Foncin JF; Spillantini MG; Puccio G
Neurology; 2010 Mar; 74(10):798-806. PubMed ID: 20164095
[TBL] [Abstract][Full Text] [Related]
9. Enhanced brain activity may precede the diagnosis of Alzheimer's disease by 30 years.
Mondadori CR; Buchmann A; Mustovic H; Schmidt CF; Boesiger P; Nitsch RM; Hock C; Streffer J; Henke K
Brain; 2006 Nov; 129(Pt 11):2908-22. PubMed ID: 17012294
[TBL] [Abstract][Full Text] [Related]
10. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
11. Brain [18F]FDDNP binding and glucose metabolism in advanced elderly healthy subjects and Alzheimer's disease patients.
Tauber C; Beaufils E; Hommet C; Ribeiro MJ; Vercouillie J; Vierron E; Mondon K; Cottier JP; Gissot V; Guilloteau D; Camus V
J Alzheimers Dis; 2013; 36(2):311-20. PubMed ID: 23609763
[TBL] [Abstract][Full Text] [Related]
12. Data-driven models of dominantly-inherited Alzheimer's disease progression.
Oxtoby NP; Young AL; Cash DM; Benzinger TLS; Fagan AM; Morris JC; Bateman RJ; Fox NC; Schott JM; Alexander DC
Brain; 2018 May; 141(5):1529-1544. PubMed ID: 29579160
[TBL] [Abstract][Full Text] [Related]
13. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
14. Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.
Smith R; Wibom M; Olsson T; Hägerström D; Jögi J; Rabinovici GD; Hansson O
J Alzheimers Dis; 2016; 51(2):339-43. PubMed ID: 26836192
[TBL] [Abstract][Full Text] [Related]
15. Glucose metabolism and PIB binding in carriers of a His163Tyr presenilin 1 mutation.
Schöll M; Almkvist O; Axelman K; Stefanova E; Wall A; Westman E; Långström B; Lannfelt L; Graff C; Nordberg A
Neurobiol Aging; 2011 Aug; 32(8):1388-99. PubMed ID: 19796846
[TBL] [Abstract][Full Text] [Related]
16. Assessment of mental deterioration with the Cognitive Abilities Screening Instrument (CASI) and glucose hypometabolism in Alzheimer's disease: the Osaki-Tajiri Project.
Yamaguchi S; Meguro K; Ishii H; Meguro M; Akanuma K
J Clin Neurosci; 2009 Nov; 16(11):1430-4. PubMed ID: 19632119
[TBL] [Abstract][Full Text] [Related]
17. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees.
Klunk WE; Price JC; Mathis CA; Tsopelas ND; Lopresti BJ; Ziolko SK; Bi W; Hoge JA; Cohen AD; Ikonomovic MD; Saxton JA; Snitz BE; Pollen DA; Moonis M; Lippa CF; Swearer JM; Johnson KA; Rentz DM; Fischman AJ; Aizenstein HJ; DeKosky ST
J Neurosci; 2007 Jun; 27(23):6174-84. PubMed ID: 17553989
[TBL] [Abstract][Full Text] [Related]
18. Decreased cortical glucose metabolism in converters from CDR 0.5 to Alzheimer's disease in a community: the Osaki-Tajiri Project.
Ishii H; Ishikawa H; Meguro K; Tashiro M; Yamaguchi S
Int Psychogeriatr; 2009 Feb; 21(1):148-56. PubMed ID: 19040787
[TBL] [Abstract][Full Text] [Related]
19. Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.
Thordardottir S; Rodriguez-Vieitez E; Almkvist O; Ferreira D; Saint-Aubert L; Kinhult-Ståhlbom A; Thonberg H; Schöll M; Westman E; Wall A; Eriksdotter M; Zetterberg H; Blennow K; Nordberg A; Graff C
Alzheimers Res Ther; 2018 May; 10(1):45. PubMed ID: 29747683
[TBL] [Abstract][Full Text] [Related]
20. [Familial Alzheimer's disease with presenilin 2 N141I mutation. A case report].
Nikisch G; Wiedemann G; Kiessling B; Hertel A
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):606-9. PubMed ID: 18833506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
